#USA #London #ACM #AMO Pharma #FDA feedback

AMO Pharma Collaborates for Breakthrough in Arrhythmogenic Cardiomyopathy Treatment

In a significant stride towards advancing treatment options for arrhythmogenic cardiomyopathy (ACM), AMO Pharma Limited, a clinical-stage biopharmaceutical company, has achieved a notable milestone with guidance from the U.S. Food and Drug Administration (FDA). In collaboration with Population Health Research Institute (PHRI) and Venca Research Inc., AMO Pharma has received crucial feedback on the potential Phase 3 development pathway for AMO-02, its investigational product targeting ACM.

Dr. Mike Snape, CEO of AMO Pharma, emphasized the importance of the FDA's input in defining the development pathway for AMO-02. This feedback elucidates essential factors regarding trial protocol and primary outcome measures, which are vital in establishing a clear framework for the anticipated Phase 3 study. "The ongoing challenges presented by ACM highlight the pressing need for effective treatments that go beyond merely managing symptoms," stated Dr. Snape, underscoring the life-threatening nature of the condition.

Arrhythmogenic cardiomyopathy is a rare inherited heart disease that can lead to severe complications, including heart failure and sudden cardiac death. It is predominantly driven by genetic mutations that cause abnormal activity of the enzyme GSK3β in cardiac cells. Among the various types of ACM, arrhythmogenic right ventricular cardiomyopathy (ARVC) is most common, significantly affecting the right ventricle. The FDA's insight revolved around determining suitable efficacy endpoints for forthcoming trials, suggesting that an endpoint characterizing the impact on implantable cardioverter-defibrillator (ICD) therapies for ventricular tachycardia (VT), such as shock delivery, could substantiate the effectiveness of AMO-02 as a treatment.

Dr. Jason Roberts, the principal investigator of the TaRGET study at PHRI, expressed optimism about the potential of AMO-02. "Patients living with ACM continually face dangerous arrhythmias and the threat of sudden cardiac death, yet most existing treatments only address symptoms and immediate risks," Dr. Roberts commented. The FDA’s guidance is expected to refine the clinical development strategy for evaluating AMO-02, enhancing research efforts aimed at addressing this critical healthcare need.

The Phase 2 TaRGET study, currently in progress and led by PHRI, is designed as a randomized, double-blind placebo-controlled trial focusing on patients with genotype-positive ACM. With a planned recruitment of 120 patients across 17 sites in Canada, the primary objective measures the change in mean premature ventricular contractions monitored through a week-long Holter assessment. Secondary outcome metrics will evaluate ventricular strain via echocardiography and document the frequency of ICD interventions, alongside incidents of sustained ventricular tachycardia. Notably, the trial's primary endpoint diverges from what has been discussed for the prospective Phase 3 study, reflecting the complexities inherent in clinical research for such rare diseases.

AMO Pharma’s dedication to addressing substantial unmet medical needs is underscored by its ongoing efforts to advance AMO-02 for various serious conditions, including congenital myotonic dystrophy type 1 and other severe disorders with limited treatment avenues. While the guidance from the FDA is instrumental, it is essential to note that such advice remains non-binding, underscoring the continuously evolving landscape of drug development and regulatory interaction. First results from the TaRGET study are projected for release in 2028, raising hopes for a transformative impact on the treatment landscape for ACM.

For more details on AMO Pharma's ongoing commitment to advancing therapies for rare genetic disorders, visit AMO Pharma's website.